Journal of Pharmaceutical and Biomedical Sciences

Login
Select Language
Subscription Login to verify subscription
Give a gift subscription
Article Tools
Print this article
Indexing metadata
How to cite item
Finding References
Review policy
Email this article (Login required)
Email the author(Login required)
Post a Comment (Login required)

Liver Abnormality in Carriers of Hepatitis B Virus (HBV)

Feroz Awadelkarim Elsayed, Omer Balla Ibrahim, Selma Ali Albashir

Abstract


Background Viral hepatitis is a first-rate human global health problem. It is far anticipated that 40% of the world’s population has had contact with or are carriers of the hepatitis B virus (HBV). The enzymes and elements that are involved in chronic liver diseases may have a direct hepatic toxicity or may be decreased as a consequence of impaired liver function.
Methods The case–control study to investigate the abnormality in the liver of carriers with HBV was conducted in Khartoum state during the period from March to April 2016. A total of 80 donors (40 male healthy control and 40 male carriers) were enrolled to investigate the abnormality of liver function by estimating the levels of T. bilirubin using vox method, direct bilirubin using vox method, albumin using bromocresol green method, AST using IFCC method, ALT using IFCC method and serum copper using atomic absorption spectrophotometer.
Results The mean values of serum albumin in carriers and the control group were 4.035 g/dL ± 0.53 and 4.6175 g/dL ± 0.26, respectively. The mean values of serum copper in carriers and the control group were 0.551 mg/L ± 0.22 and 0.7003 mg/L ± 0.12, respectively. The above values were statistically significantly decreased when compared to the control group (P values 0.000). The mean values of serum T. bilirubin in carriers and the control group were 0.387 mg/dL ± 0.23 and 0.4 377 mg/dL ± 0.28, respectively. The mean values of serum direct bilirubin in carriers and the control group were 0.134 mg/dL ± 0.11 and 0.1548 mg/dL ± 0.12, respectively. The mean values of serum AST in carriers and the control group were 18.85 IU/L ± 4.02 and 22.05 IU/L ± 10.91, respectively. The mean values of serum ALT in carriers and the control group were 25.35 IU/L ± 20.91 and 21.725 IU/L ± 8.02, respectively. There were no significant differences in the mean values of bilirubin (T and D), AST and ALT when compared to control group (P values > 0.05).
Conclusion The results presented in this study showed statistically significant decreases in both serum albumin and copper levels in carriers when compared to control group. There were no significant differences between the HBV carriers and control group regarding the levels of T. bilirubin, direct bilirubin, AST and ALT in our study.

Keywords


T. bilirubin, direct bilirubin, albumin, AST, ALT, serum copper, HBV, carriers

Full Text:

References


Jafri N, Yakoob J, Islam M, Tirmizi SF, Jafar T, et al. Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. BMC Infect Dis. 2006;6:101–105.

Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34(6):1329–39.

Wang Y, Wei L, Jiang D, Cong X, Fei R, Xiao J, et al. In vitro resistance to interferon of hepatitis B virus with precore mutation. World J Gastroenterol. 2005;11(5):649–655.

Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis: United States, 2006. MMWR Surveill Summ. 2008;57(2):1.

Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe: a review. Euro Surveill. 2008;13(21).

Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14(27):4300.

Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, et al. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements. 2008;25(2):1–29.

Taysi S, Akcay F, Uslu C, Dogru Y, Gulcin I. Trace elements and some extra cellular antioxidant proteins levels in serum of patients with laryngeal cancer. Biol Trace Element Res.2003;91:11–18.

Loguercio C, De Girolamo V, Federico A, Feng SL, Crafa E, Cataldi V, et al. Relationship of blood trace elements to liver damage, nutritional status, and oxidative stress in chronic nonalcoholic liver disease. Biol Trace Elem Res. 2001;81(3):245–54.

Meram I, Sirmatel F, Ahi S, Tarakcioglu M. Plasma copper and zinc levels in chronic viral hepatitis. Saudi Med J. 2004;25(8):1066–9.

Reddy NRP, Kishore A, Franklin A, Reddy EP. Evaluation of trace elements in hepatitis B. J Pharm Biomed Sci. 2012;21(07):ISSN No:2230–7885.

Limdi JK, Hyde GM. Evaluation of abnormal liver function tests; Postgrad Med J. 2003;79:307–312.

Lin CC, Huang JF, Tsai LY, Huang YL. Selenium, iron, copper, and zinc levels and copper to zinc ratios in serum of patients at different stages of viral hepatic diseases. Biol Trace Elem Res. 2006;109(1):15–24.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.